Inhibrx Biosciences (INBX) vs Kailera Therapeutics (KLRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Inhibrx Biosciences is the larger company by market cap ($1.40 billion vs $1.39 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INBX | KLRA |
|---|---|---|
| Share price | $94.98 | $10.72 |
| Market cap | $1.40B | $1.39B |
| 1-day change | +2.39% | +7.20% |
| YTD return | +17.42% | — |
| 1-year return | +175.99% | — |
| EPS (TTM) | $-8.88 | $-4.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $155.29 | $28.23 |
| 52-week low | $28.16 | $9.76 |
| Distance from 52-week high | -38.84% | -62.03% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +180.76% | +295.52% |
| Average volume | 284.58K | 861.01K |
| Shares outstanding | 14.72M | 129.64M |
| Employees | 109 | 145 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Inhibrx Biosciences
INBX stock →Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Kailera Therapeutics
KLRA stock →Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
INBX vs KLRA FAQ
Which is bigger, Inhibrx Biosciences or Kailera Therapeutics?
Inhibrx Biosciences (INBX) is larger, with a market capitalization of $1.40B compared with $1.39B for Kailera Therapeutics (KLRA).
Are Inhibrx Biosciences and Kailera Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Inhibrx Biosciences and Biotechnology: Pharmaceutical Preparations for Kailera Therapeutics.